FDA tracker
Semaglutide: FDA regulatory status
FDA approvedUpdated Apr 23, 2026
FDA approved 2017 (T2D), 2021 (obesity)
Editorially reviewedThe Peptide Examiner editorial team, Editorial review · Reviewed Apr 23, 2026
Regulatory timeline
Feb 21, 2025 · Shortage
FDA declares semaglutide shortage resolved
503A compounding discretion ended April 22, 2025; 503B by May 22, 2025. Compounded semaglutide no longer broadly legal.
Dec 10, 2024 · Warning letter
FDA warning letters to research peptide vendors
Summit Research Peptides, Prime Peptides, Xcel Peptides, and SwissChems received warning letters for selling semaglutide as unapproved drug under research-use-only labeling.
What this means for patients
Semaglutide is FDA approved. Access is through a clinician prescription and a licensed pharmacy. Insurance coverage depends on the approved indication and your plan's formulary.